Table of contents


Please note that this product (marketed as Refixia) was withdrawn from the Community Register of designated orphan medicinal products in May 2017 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 15 May 2009, orphan designation (EU/3/09/640) was granted by the European Commission to Novo Nordisk A/S, Denmark, for pegylated recombinant human factor IX for the treatment of haemophilia B.

This medicine is now known as nonacog beta pegol.

Key facts

Active substance
Pegylated recombinant human factor IX (nonacog beta pegol)
Disease / condition
Treatment of haemophilia B
Date of first decision
EU designation number

Sponsor's contact details

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Tel. +45 44 44 88 88

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating